Trial
NCT02658916
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Biogen
Collaborators
—
Condition
Supranuclear Palsy, Progressive
Intervention
BIIB092
Why stopped
251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-18